-
公开(公告)号：KR101885114B1
公开(公告)日：2018-08-03
申请号：KR1020160142720
申请日：2016-10-31
Applicant: 강원대학교산학협력단
IPC: A61K48/00
Abstract: 본발명은신테닌(syntenin)을표적으로한 siRNA 또는 shRNA를포함하는혈관신생억제용조성물에관한것으로, 신테닌 siRNA 또는 shRNA의처리를통해혈관내피세포에서의신테닌발현이억제되었고, 억제된신테닌에의해 VEGF 유도혈관신생이억제된것을확인하였다. 이를통해, 본발명의신테닌 siRNA 또는 shRNA는혈관내피세포에직접적으로작용하여혈관신생과다로인한질환을예방또는치료하는데이용될수 있을것으로기대된다.
-
公开(公告)号：KR102014241B1
公开(公告)日：2019-08-26
申请号：KR1020180020631
申请日：2018-02-21
Applicant: 강원대학교산학협력단
IPC: A61K31/352 , A23L33/10 , A61P19/10
-
公开(公告)号：KR101646916B1
公开(公告)日：2016-08-09
申请号：KR1020150098984
申请日：2015-07-13
Applicant: 강원대학교산학협력단
IPC: A61K31/437 , A23L1/30
Abstract: 본발명은신규 7-메톡시-(9H-베타-카르볼린-1-일)-()-2-프로페노익산화합물을함유하는염증성질환의예방또는치료용조성물에관한것이다. 상기 7-메톡시-(9H-베타-카르볼린-1-일)-()-2-프로페노익산은전사인자인 Nrf2의활성화를통해 HO-1(heme oxgenase-1)의발현을증가시켜염증성사이토카인및 각종염증인자의발현을억제함으로써, 염증성장질환, 죽상동맥경화, 염증성콜라겐혀로간질환, 사구체신염, 염증성피부질호나, 유육종증, 망막염, 위염, 간염, 장염, 관절염, 편도선염, 인후염, 기관지염, 폐렴, 췌장염, 패혈증, 신장염등과같은각종질환의치료제나건강기능식품으로서용이하게이용될수 있다.
Abstract translation: 本发明涉及一种组合物，其包含用于预防或治疗炎症性疾病的新化合物7-甲氧基 - （9H-β-咔啉-1-基） - （E） - 丙酸。 化合物7-甲氧基 - （9H-β-咔啉-1-基） - （E） - 丙酸通过Nrf2作为转录因子的活化而增加HO-1（血红素加氧酶-1）的表达，以抑制表达 的炎性细胞因子和各种炎症因子。 因此，该化合物可用于治疗炎症性肠病，动脉粥样硬化，炎性胶原血管疾病，肾小球性肾炎，炎性皮肤病，结节病，视网膜炎，胃炎，肝炎，肠炎，关节炎，扁桃体炎，喉咽炎，支气管炎 ，肺炎，胰腺炎，败血症，肾炎等。
-
公开(公告)号：KR101339728B1
公开(公告)日：2013-12-11
申请号：KR1020110128028
申请日：2011-12-02
Applicant: 강원대학교산학협력단
IPC: A61K31/047 , A61K31/045 , A61K31/20 , A61P9/00
Abstract: 본 발명은 말라바리콘 C(malabaricone C)를 유효성분으로 함유하는 평활근 세포의 증식 또는 이동 억제 효과가 있는 조성물에 관한 것으로, 상기 조성물은 동맥경화증, 고혈압, 협심증, 심근경색, 허혈성 심장질환, 심부전, 경혈관 동맥 성형술 후 발생하는 합병증, 뇌경색, 뇌출혈, 및, 뇌졸중 등과 같은 혈관 질환을 예방 및 치료할 수 있으며, 상기 질병들을 개선할 수 있는 다양한 치료제에도 유용하게 응용될 수 있다.
-
5.发明授权에리스로-(7에스,8알)-7-아세톡시-3,4,3'',5''-테트라메톡시-8-O-4''-네오리그난을 함유하는 혈관질환의 치료 또는 예방용 조성물 有权包含用于治疗或预防血管疾病的ERYTHRO-（7S，8R）-7-乙酰氧基-3,4,3'，5'-四甲氧基-8-O-4'-非极性组合物
公开(公告)号：KR101333669B1
公开(公告)日：2013-11-28
申请号：KR1020120122775
申请日：2012-11-01
Applicant: 강원대학교산학협력단
IPC: A61K31/05 , A61K31/045 , A61P9/10 , A61P9/00
Abstract: The present invention relates to a composition containing erythro-(7S,8R)-7-acetoxy-3,4,3',5'-tetramethoxy-8-O-4'-neolignan for preventing or treating vascular diseases. The composition containing erythro-(7S,8R)-7-acetoxy-3,4,3',5'-tetramethoxy-8-O-4'-neolignan effectively suppresses platelet aggregation, thereby being used as a composition for effectively preventing and suppressing vascular diseases including thrombosis, arteriosclerosis, angina pectoris, myocardial infarction, ischemic heart disease, heart failure, complications after percutaneous transluminal coronary angioplasty, cerebral infarction, cerebral hemorrhage, and stroke. [Reference numerals] (AA,BB,CC) Blood platelet cohesion activation (%)
Abstract translation: 本发明涉及含有用于预防或治疗血管疾病的红 - （7S，8R）-7-乙酰氧基-3,4,3'，5'-四甲氧基-8-O-4'-新替尼利因的组合物。 含有红 - （7S，8R）-7-乙酰氧基-3,4,3'，5'-四甲氧基-8-O-4'-新衣肉酸酯的组合物有效地抑制血小板聚集，从而被用作有效预防和/ 抑制血管疾病，包括血栓形成，动脉硬化，心绞痛，心肌梗塞，缺血性心脏病，心力衰竭，经皮腔内冠状动脉成形术，脑梗塞，脑出血和中风后的并发症。 （附图标记）（AA，BB，CC）血小板内聚活化（％）
-
Patent Agency Ranking
公开(公告)号：KR1020110095611A
公开(公告)日：2011-08-25
申请号：KR1020100015177
申请日：2010-02-19
Applicant: 강원대학교산학협력단
CPC classification number: A61K38/1841
Abstract: PURPOSE: A pharmaceutical composition containing MIC-1 gene or expression protein thereof is provided to be used for wound healing as a therapeutic agent. CONSTITUTION: A pharmaceutical composition for wound healing contains MIC-1(macrophage inhibitory cytokine-1) gene or expression protein thereof as an active ingredient. The MIC-1 gene encodes an amino acid of sequence number 2 or 7. The MIC-1 gene is inserted to a recombinant vector. The MIC-1 protein has an amino acid sequence of sequence number 2 or 7. The MIC-1 protein is expressed from the expression vector.
Abstract translation: 目的：提供含有MIC-1基因或其表达蛋白质的药物组合物作为治疗剂用于伤口愈合。 构成：用于伤口愈合的药物组合物含有MIC-1（巨噬细胞抑制性细胞因子-1）基因或其表达蛋白作为活性成分。 MIC-1基因编码序列号为2或7的氨基酸。将MIC-1基因插入重组载体。 MIC-1蛋白具有序列号2或7的氨基酸序列。表达载体表达MIC-1蛋白。
-
公开(公告)号：KR20180047061A
公开(公告)日：2018-05-10
申请号：KR20160142720
申请日：2016-10-31
Applicant: 강원대학교산학협력단
IPC: A61K48/00
CPC classification number: A61K48/00 , Y10S514/825 , Y10S514/863 , Y10S514/912 , Y10S514/913
Abstract: 본발명은신테닌(syntenin)을표적으로한 siRNA 또는 shRNA를포함하는혈관신생억제용조성물에관한것으로, 신테닌 siRNA 또는 shRNA의처리를통해혈관내피세포에서의신테닌발현이억제되었고, 억제된신테닌에의해 VEGF 유도혈관신생이억제된것을확인하였다. 이를통해, 본발명의신테닌 siRNA 또는 shRNA는혈관내피세포에직접적으로작용하여혈관신생과다로인한질환을예방또는치료하는데이용될수 있을것으로기대된다.
-
公开(公告)号：KR101317671B1
公开(公告)日：2013-10-15
申请号：KR1020110080948
申请日：2011-08-16
Applicant: 강원대학교산학협력단
IPC: A61K31/70 , A61K31/353 , A61K31/35 , A61P35/00
Abstract: 본 발명은 2-데옥시글루코스와 테프로신을 유효성분으로 하는 암 예방 또는 치료용 조성물에 관한 것으로, 테프로신은 세포 내 ATP 양을 감소시키고 2-데옥시글루코스가 유도하는 자가포식 현상을 억제할 수 있는 것으로 확인된다. 따라서, 상기 테프로신과 2-데옥시글루코스를 암세포에 병용처리할 경우, 각각의 화합물을 단독처리할 때보다 암세포의 사멸효과를 증강시킬 수 있으며, 상기와 같은 효과는 다양한 암세포에서 모두 나타나는 것으로 확인된다.
-
公开(公告)号：KR1020130061782A
公开(公告)日：2013-06-12
申请号：KR1020110128028
申请日：2011-12-02
Applicant: 강원대학교산학협력단
IPC: A61K31/047 , A61K31/045 , A61K31/20 , A61P9/00
Abstract: PURPOSE: A composition containing malabaricone C as an active ingredient is provided to suppress proliferation or migration of smooth muscle cells, and to prevent or treat vascular diseases such as hypertension, angina pectoris, cardiac infarction, ischemic heart diseases, heart failure, complication occurred after transluminal angioplasty, ischemic stroke, cerebral hemorrhage, and stroke. CONSTITUTION: A pharmaceutical composition for preventing or treating vascular diseases contains malabaricone C with a structure of chemical formula 1. The vascular diseases are selected from the group consisting of atherosclerosis, hypertension, angina pectoris, ischemic heart diseases, heart failure, complication occurred after transluminal angioplasty, ischemic stroke, cerebral hemorrhage, and stroke. The pharmaceutical composition induces expression of HO-1(heme oxygenase-1) in vascular smooth muscle cells. The pharmaceutical composition suppresses proliferation or migration of vascular smooth muscle cells.
Abstract translation: 目的：提供含有malabaricone C作为活性成分的组合物，以抑制平滑肌细胞的增殖或迁移，并预防或治疗血管疾病如高血压，心绞痛，心肌梗塞，缺血性心脏病，心力衰竭，并发症发生在 经腔血管成形术，缺血性卒中，脑出血和中风。 构成：用于预防或治疗血管疾病的药物组合物含有具有化学式1结构的malabaricone C.血管疾病选自动脉粥样硬化，高血压，心绞痛，缺血性心脏病，心力衰竭，经腔内发生并发症 血管成形术，缺血性中风，脑出血和中风。 药物组合物诱导血管平滑肌细胞中HO-1（血红素加氧酶-1）的表达。 药物组合物抑制血管平滑肌细胞的增殖或迁移。
-
公开(公告)号：KR1020130019043A
公开(公告)日：2013-02-26
申请号：KR1020110080948
申请日：2011-08-16
Applicant: 강원대학교산학협력단
IPC: A61K31/70 , A61K31/353 , A61K31/35 , A61P35/00
CPC classification number: A61K31/7004 , A23L2/52 , A23L29/035 , A23L29/30 , A23V2200/308 , A61K31/353
Abstract: PURPOSE: A composition containing 2-deoxyglucose and tephrosin for preventing or treating cancer is provided to suppress autophage and to enhance cancer cell apoptosis. CONSTITUTION: A pharmaceutical composition for preventing or treating cancer contains 2-deoxyglucose of chemical formula 1 and tephrosin of chemical formula 2 as active ingredients. Tephrosin suppress autophage induced by 2-deoxyglucose. A health function food for preventing or treating cancer contains deoxyglucose of chemical formula 1 and tephrosin of chemical formula 2 as active ingredients. The health functional food is manufactured in the form of a drink, meats, sausage, breads, candy, snacks, noodles, ice cream, soup, and nutrient.
Abstract translation: 目的：提供含有2-脱氧葡萄糖和酪蛋白用于预防或治疗癌症的组合物，以抑制自噬和增强癌细胞凋亡。 构成：用于预防或治疗癌症的药物组合物含有化学式1的2-脱氧葡萄糖和化学式2的酪蛋白作为活性成分。 Tephrosin抑制由2-脱氧葡萄糖诱导的自噬。 用于预防或治疗癌症的保健功能食品含有化学式1的脱氧葡萄糖和化学式2的酪蛋白作为活性成分。 健康功能食品以饮料，肉类，香肠，面包，糖果，小吃，面条，冰淇淋，汤和营养物的形式制造。
-
-
-
-
-
-
-
-
-
Search Results
19
records
(took 0.021 seconds)
